SCHEMBL3535153

SCHEMBL3535153

CC(=O)c1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
HSD17B1 P14061 2/20 0.64
KMT2A Q03164 3/20 0.62
MEN1 O00255 2/20 0.62
RAB9A P51151 2/20 0.62
NPC1 O15118 1/20 0.62
HTT P42858 1/20 0.62
NLRP1 Q9C000 1/20 0.62
MAOA P21397 1/20 0.55
MAOB P27338 1/20 0.55
CES2 O00748 2/20 0.54
CES1 P23141 2/20 0.54
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
KDM4E B2RXH2 1/20 0.51
TP53 P04637 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28193245 0.93 MAPT (0.69) MAPTSMN1; SMN2HSD17B1KMT2AMEN1
SCHEMBL17187946 0.93 MAPT (0.69) MAPTSMN1; SMN2HSD17B1KMT2AMEN1
SCHEMBL75640 0.93 MAPT (0.69) MAPTSMN1; SMN2HSD17B1KMT2AMEN1
Ammonia Solution, Strong SCHEMBL17180520 0.90 MAPT (0.67) MAPTSMN1; SMN2HSD17B1KMT2AMEN1
Hydrochloric Acid SCHEMBL27858043 0.90 MAPT (0.67) MAPTSMN1; SMN2HSD17B1KMT2AMEN1
Nitrogen SCHEMBL27858242 0.88 MAPT (0.64) MAPTSMN1; SMN2HSD17B1KMT2AMEN1
SCHEMBL197130 0.87 MAPT (0.80) MAPTSMN1; SMN2HSD17B1KMT2ARAB9A
SCHEMBL11441494 0.87 MAPT (0.80) MAPTSMN1; SMN2HSD17B1KMT2ARAB9A
Carbon Monoxide SCHEMBL10625076 0.86 MAPT (0.62) MAPTSMN1; SMN2HSD17B1KMT2AMEN1
SCHEMBL31186097 0.86 SRD5A2 (0.64) MAPTSMN1; SMN2KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573086-A1 METHANOGEN INHIBITORS Agrizeronz Limited Partnership (NZ) 2025-06-25 EP disclosed
CN-119998272-A Methanogen inhibitors 阿格里泽伦茨有限合伙公司 2025-05-13 CN disclosed
CN-113825735-B Carbon-carbon bond formation method 奥加诺株式会社 2025-01-07 CN disclosed
WO-2024039250-A1 METHANOGEN INHIBITORS PASTORAL GREENHOUSE GAS RESEARCH LIMITED (NZ) 2024-02-22 WO disclosed
US-20220168723-A1 METHOD FOR FORMING CARBON-CARBON BOND ORGANO CORPORATION (JP) 2022-06-02 US disclosed
US-20220168723-A1 METHOD FOR FORMING CARBON-CARBON BOND ORGANO CORPORATION (JP) 2022-06-02 US disclosed
EP-3971156-A1 METHOD FOR FORMING CARBON-CARBON BOND Organo Corporation (JP) 2022-03-23 EP disclosed
US-20220024980-A1 LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF BIOPHARMA CREDIT PLC (GB) 2022-01-27 US disclosed
CN-113825735-A Method for forming carbon-carbon bond 奥加诺株式会社 2021-12-21 CN disclosed
EP-3587406-B1 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER FORMA THERAPEUTICS INC (US) 2021-01-27 EP disclosed
US-6649619-B1 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl) benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimeth ylenepyrimidin-4-one or salt; lipoprotein-associated phospholipase A inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2003-11-18 US disclosed
WO-2003082852-A1 NOVEL SUBSTITUTED 1,2,4-TRIOXANES USEFUL AS ANTIMALARIAL AGENTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-10-09 WO disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed
CN-1082023-A The medicine and the novel benzoic acid derivative that contain benzoic acid derivative YAMANOUCHI PHARMA CO LTD (JP) 1994-02-16 CN disclosed
US-4239759-A Morpholino containing compounds, compositions and use thereof MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1980-12-16 US disclosed
US-4125612-A N-1-(p-Biphenylalkyl)piperazines and their use as anti-inflammatory agents SCHERING CORPORATION (US) 1978-11-14 US disclosed
US-4110447-A Anti-inflammatory (halo-4-biphenylyl)-alkanolamines MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1978-08-29 US disclosed
US-4027041-A Ethyl- and vinylbenzenes as antithrombotic agents ELI LILLY AND COMPANY (US) 1977-05-31 US disclosed
US-4024284-A Ethyl- and vinylbenzenes as anti-inflammatory agents ELI LILLY AND COMPANY (US) 1977-05-17 US disclosed
US-3975542-A Ethyl- and vinylbenzenes as antithromobiotic agents ELI LILLY AND COMPANY (US) 1976-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024980-A1 LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF PGLS, LGALS3BP, LNPEP MAPT 4457/4885SMN1; SMN2 4822/4885HSD17B1 2436/4885
US-20220168723-A1 METHOD FOR FORMING CARBON-CARBON BOND SLC40A1, SLCO4C1, NUP93 MAPT 3193/4885SMN1; SMN2 3496/4885HSD17B1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.